Related Experiment Videos
Restenosis after multilesion percutaneous transluminal coronary angioplasty
Insights
Percutaneous transluminal coronary angioplasty (PTCA) offers immediate symptom relief for multivessel coronary disease. While restenosis rates are higher after multiple lesions, it remains a viable option for selected patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Multivessel coronary disease is increasingly treated with percutaneous transluminal coronary angioplasty (PTCA).
- PTCA provides immediate symptomatic relief but long-term benefits and restenosis rates after multiple lesions require further investigation.
Purpose of the Study:
- To determine the incidence and clinical significance of restenosis after multilesion PTCA.
- To compare restenosis rates after multilesion PTCA with single-lesion PTCA.
- To inform expanded indications for multilesion PTCA.
Main Methods:
- Review of existing data on multilesion PTCA outcomes.
- Analysis of reported restenosis rates and clinical significance.
- Comparison of recurrence rates across different patient series and single-lesion procedures.
Main Results:
- The risk of at least one recurrent lesion after multilesion PTCA ranges from 26% to 53%.
- Multilesion restenosis occurs in 7% to 21% of patients, often associated with recurrent symptoms.
- Silent multilesion restenosis is rare.
Conclusions:
- Multilesion PTCA is safe and effective for immediate symptom relief in selected patients with multivessel coronary disease.
- Higher restenosis rates should not deter its use, as recurrent lesions are often treatable with repeat procedures.
- Further standardization in defining restenosis and patient selection is needed for better comparison of study outcomes.
Abstract:
Experience and new technical advances have resulted in an increasing number of patients with multivessel coronary disease who can be considered for percutaneous transluminal coronary angioplasty (PTCA). In selected patients with multivessel coronary disease, PTCA is a safe and effective procedure for the immediate relief of anginal symptoms. However, many questions remain regarding the long-term therapeutic benefit of the procedure. Few data are available on the incidence and clinical significance of restenosis after multilesion PTCA. Clearly, there is the potential for a higher rate of restenosis in patients who undergo dilatation of more than 1 lesion. Determination of restenosis rates after multilesion PTCA is important in the definition of expanded indications for this procedure. Because of the variations in definitions of restenosis and in patient selection factors, reported recurrence rates after multilesion PTCA are not easily compared between patient series. After multilesion dilatation the risk of developing at least 1 recurrent lesion ranges from 26% to 53% and appears to be greater than that reported for single lesion PTCA. Multilesion restenosis occurs in 7% to 21% of patients who undergo multilesion PTCA and is frequently observed in patients with recurrent symptoms. "Silent" multilesion restenosis (i.e., multiple lesion restenosis without symptoms) is rare. A higher risk of restenosis at one of several dilatation sites in a patient with extensive coronary disease should not be a deterrent in recommending multilesion PTCA to selected patients with multivessel coronary disease because the procedure provides important symptomatic relief to most. Further, recurrent narrowings are usually amenable to a second dilatation attempt if clinically indicated.